Centers for Disease Control and Prevention – Page 2

HPV vaccine myths put health, lives at risk, say health leaders: Airing the facts

Source: TheNationsHealth.org Vaccination rates for human papillomavirus are lagging for teens, and a complicated web of confusion and misinformation may be to blame, according to public health leaders. Several strains of HPV can cause cervical cancer, and two vaccines, Gardasil and Cervarix, have been shown conclusively to defend against those strains. The Food and Drug Administration recommended in 2006 that girls receive the vaccine before they become sexually active so that they are protected at the outset. In 2009, FDA approved the use of the vaccine for boys as well. According to the Centers for Disease Control and Prevention, about 6 million people in the U.S. become infected with HPV each year and each year about 12,000 women are diagnosed with cervical cancer, leading to about 4,000 deaths. Studies have shown the vaccine to be overwhelmingly safe, CDC said. As of June 2011, about 35 million doses of Gardasil had been distributed in the United States. CDC’s adverse event tracking mechanisms reported about 18,000 adverse events, 92 percent of which were nonserious events, such as fainting, swelling at the injection site and headache. Sixty-eight deaths were reported, but there is “no unusual pattern or clustering to the deaths that would suggest that they were caused by the vaccine, and some reports indicated a cause of death unrelated to vaccination,” CDC said. And yet, fed perhaps by misinformation or squeamishness about the idea of their children becoming sexually active, some parents are opting not to vaccinate, and the vaccination rates are [...]

Oral Cancer Foundation News Team - A2011-12-01T12:41:51-07:00December, 2011|Oral Cancer News|

Implications of the Oropharyngeal Cancer Epidemic

Source: Journal of Clinical Oncology Chaturvedi et al,1 analyzing specimens back to 1984, validate the long-held hypothesis that infection with human papillomavirus (HPV) has increased oropharyngeal squamous cell carcinoma (OPSCC) incidence in the US. They find the incidence of OPSCC in men—who have higher risks of both HPV-positive and HPV-negative OPSCC than women—similar to that of cervical cancer in women. From 1988 to 2004, incidence of HPV-negative OPSCC decreased in parallel with smoking whereas incidence of HPV-positive OPSCC increased at about 7.5% per year, so the percentage of OPSCC that was HPV-positive went from less than 20% to more than 70%. HPV-positive and HPV-negative OPSCC are etiologically and clinically distinct,2,3 with HPV-positive disease having better outcome.4–6 In the current study,1 the hazard ratio of 0.3 for HPV-positive/HPV-negative in survival analysis essentially balances the difference in prevalence so each form of OPSCC now accounts for a similar number of deaths. Notably, the authors found that outcomes for HPV-positive OPSCC have improved over time, whereas outcomes for HPV-negative OPSCC are as dismal as they were 25 years ago. The authors argue convincingly that vaccination to prevent oral HPV infections should be evaluated and that better treatments for both types of OPSCC should be developed. We are unlikely to get a better picture of the recent history of OPSCC in the United States. This study used all available OPSCC specimens from the three Surveillance, Epidemiology, and End Results (SEER) registries that participate in the Residual Tissue Repositories Program, analyzed them in several ways, [...]

Oral Cancer Foundation News Team - A2011-11-09T15:24:59-07:00November, 2011|Oral Cancer News|

Kentucky Cancer Center Urges Smokers to Switch to Smoke-Free Tobacco. But is it Really a Better Option?

Source: Yourlife.USAtoday.com In the smoker-heavy state of Kentucky, a cancer center is suggesting something that most health experts won't and the tobacco industry can't: If you really want to quit, switch to smoke-free tobacco. The James Graham Brown Cancer Center and the University of Louisville are aiming their "Switch and Quit" campaign at the city of Owensboro. It uses print, radio, billboard and other advertising to urge smokers to swap their cigarettes for smokeless tobacco and other products that do not deliver nicotine by smoke. Supporters say smokers who switch are more likely to give up cigarettes than those who use other methods such as nicotine patches, and that smokeless tobacco carries less risk of disease than cigarettes do. "We need something that works better than what we have," said Dr. Donald Miller, an oncologist and director of the James Graham Brown Cancer Center, which supports the effort along with the University of Louisville. "This is as reasonable a scientific hypothesis as anybody has come up with and it needs to be tried." The campaign runs counter to the prevailing opinion of the public health community, which holds that there is no safe way to use tobacco. Federal researchers, however, have begun to at least consider the idea that smokers might be better off going smokeless. The National Cancer Institute at the National Institutes of Health says on its website that the use of all tobacco products "should be strongly discouraged," and that there is "no scientific evidence that using [...]

Oral Cancer Foundation News Team - A2011-10-31T10:04:54-07:00October, 2011|Oral Cancer News|

Cigarette Marketing Declined, but Smokeless Tobacco Marketing Doubled in Recent Years

Source: PR Newswire WASHINGTON, Aug. 1, 2011 /PRNewswire-USNewswire/ -- The following is a statement from Matthew L. Myers, President, Campaign for Tobacco-Free Kids: The Federal Trade Commission on Friday reported that cigarette marketing expenditures in the United States declined from $12.5 billion in 2006 to $10.9 billion in 2007 and $9.9 billion in 2008. The FTC also reported that smokeless tobacco marketing increased from $354.1 million in 2006 to $411.3 million in 2007 and $547.9 million in 2008. When measured from 2005, smokeless tobacco marketing has more than doubled (from $250.8 million to $547.9 million). While it is a positive step that cigarette marketing has declined, the tobacco companies continue to spend huge sums to market their deadly and addictive products. Counting both cigarette and smokeless tobacco marketing, the tobacco companies spent $10.5 billion on marketing in 2008 – nearly $29 million each day and 52 percent more than they spent at the time of the 1998 settlement of state lawsuits against the industry, which was supposed to curtail tobacco marketing. Tobacco companies in 2008 spent 20 times more to market tobacco products than the states currently spend on programs to prevent kids from smoking and help smokers quit (the states spent $517.9 million on such programs in fiscal year 2011). This huge mismatch between how much tobacco companies spend to encourage tobacco use and how much states spend to discourage it is a major contributing factor to the slowing of smoking declines in recent years. It is especially troubling [...]

Oral Cancer Foundation News Team - A2011-08-02T09:44:39-07:00August, 2011|Oral Cancer News|

HPV Vaccine- Should it be Available for Boys?

Source: Dr.Bicuspid.com July 14, 2011 -- With the alarming rise in the rate of oropharyngeal cancer among men being linked to the human papillomavirus (HPV), the U.S. Centers for Disease Control and Prevention (CDC) is considering whether to also recommend the HPV vaccine for boys. Two vaccines (Cervarix and Gardasil) are currently available to protect females against the HPV types that cause most cervical cancers. The CDC currently recommends both for 11- and 12-year-old girls and for females 13 through 26 years old who did not get the three recommended doses when they were younger. The number of HPV-related oral cancers cases among men in the U.S. is increasing so quickly they could surpass the number of cases of cervical cancers in women by 2020, according to research presented last month at the American Society of Clinical Oncology annual meeting in Chicago. Between 1984 and 1989, only 16% of oropharyngeal cancers were linked to HPV. But by 2000-2004, HPV was related to 75% of oropharyngeal cancers, according to the National Cancer Institute (NCI). In 2010, the institute estimated that there were 12,660 cases of oropharyngeal cancer, resulting in 2,410 deaths. About half of those cases were among males and at least 75% were caused by HPV, according to NCI researchers. Several studies and oral cancer specialists have attributed the sharp rise in HPV-positive oropharyngeal cancers to an increasing prevalence of oral sex among young people. For the past few years, the CDC's Advisory Committee on Immunization Practices (ACIP) has been [...]

Oral Cancer Foundation News Team - A2011-07-14T09:53:49-07:00July, 2011|Oral Cancer News|

The Value of Vaccines

Source: Medscape.com Vaccines Decrease Rate of Bacterial Meningitis A recent, retrospective study revealed that the incidence of bacterial meningitis decreased by 31% over 10 years, likely the result of vaccinations (Thigpen et al. 2011). In addition, the median age of those infected increased from 30.3 to 41.9 years, evidence that vaccinating the young has protected them from infections while leaving older, unvaccinated people more vulnerable. The authors analyzed data on bacterial meningitis from 1998-1999 to 2006-2007 in 8 surveillance areas of the Emerging Infections Programs Network, which includes 17.4 million people. The 5 most common pathogens for bacterial meningitis were Haemophilus influenza type b (Hib), Streptococcus pneumonia, group B streptococcus (GBS), Listeria monocytogenes, and Neisseria meningitides. Cerebrospinal confirmation of the clinical diagnosis was required. The beneficial effect of vaccines during the surveillance period is striking. The incidence of bacterial meningitis from Haemophilus influenza decreased by 35%. For strains of bacterial meningitis from Streptococcus pneumonia included in the PCV7 vaccine, infections decreased by 92%. Conversely, rates of meningitis from group B streptococcus, for which there is no vaccine, did not change. Deadly Choices In a recent Medscape One-on-One video interview, Eli Adashi, MD, discussed the dangers of the anti-vaccine movement with Paul Offit, MD, Chief of Infectious Disease at Children's Hospital, Philadelphia, PA. Dr. Offit is a pediatrician and author of Deadly Choices: How the Anti-Vaccine Movement Threatens Us All, Basic Books, 2011. It's a Conspiracy... According to the Centers for Disease Control and Prevention (CDC), "Unfounded claims can cause harm [...]

Oral Cancer Foundation News Team - A2011-06-29T09:50:20-07:00June, 2011|Oral Cancer News|

HPV related oral cancers continue to increase in the US

Source: International Medicine News CHICAGO – Human papillomavirus infection was firmly linked to the recent rise in oropharyngeal cancers in the United States, based on data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results program. If current trends continue, the incidence of HPV-related oral cancers will soon surpass that of cervical cancers, senior author Dr. Maura Gillison reported at the annual meeting of the American Society of Clinical Oncology. The incidence of HPV-positive oropharyngeal cancers increased 225% – from 0.8 per 100,000 to 2.8 per 100,000 – between 1988 and 2004, the researchers found. At the same time, the incidence rate for HPV-negative oropharyngeal cancers, which are strongly related to tobacco and alcohol use, declined by 50% – from 2.0 per 100,000 to 1.0 per 100,000. Consequently, the overall incidence of oropharyngeal cancers increased 28%. Even by the conservative estimate that 70% of oropharyngeal cancers in 2020 will be HPV positive, the annual number of HPV-positive oral squamous cell carcinomas (8,653 cases) is expected to surpass cervical cancers (7,726 cases). Further, the majority will occur among men (7,426 cases), said Dr. Gillison, a medical oncologist and the Jeg Coughlin Chair in Cancer Research at Ohio State University Comprehensive Cancer Center in Columbus. Changes in sexual behavior among recent birth cohorts and increased oral HPV exposure probably influenced the increases in incidence and prevalence, Dr. Gillison speculated. Having a high lifetime number of sexual partners is a known risk factor for HPV infection. Although the rise in oral cancers [...]

Oral Cancer Foundation News Team - A2011-06-06T10:23:24-07:00June, 2011|Oral Cancer News|

New Report: States Continue Drastic Cuts to Tobacco Prevention Programs

Source: Robert Wood Johnson Foundation This year (Fiscal Year 2011) states will collect $23.5 billion in revenue from the 1998 tobacco settlement funds and tobacco taxes. Alarmingly, though, the states will only spend two percent of that amount—$517.9 million—on programs to prevent smoking and help smokers quit. That’s the lowest amount of tobacco prevention program funding since 1999, when the states first received tobacco settlement funds, according to a report released today by a coalition of public health organizations, including the Robert Wood Johnson Foundation (RWJF). U.S. adult smoking rates have stalled at 20.6 percent after decades of decline. Echoing the recommendations of major public health organizations such as the Institute of Medicine, the President’s Cancer Panel and the Centers for Disease Control and Prevention, the report recommends that states increase funding for tobacco prevention and cessation programs, increase tobacco taxes and enact strong smoke-free laws that apply to all workplaces, restaurants and bars. In addition, the federal government should robustly fund and implement the national tobacco prevention strategy unveiled on November 10, 2010 by the U.S. Department of Health and Human Services. The report, titled “A Broken Promise to Our Children: The 1998 State Tobacco Settlement 12 Years Later,” was released by the Campaign for Tobacco-Free Kids, American Heart Association, American Cancer Society Cancer Action Network, American Lung Association and RWJF. These organizations have issued yearly reports assessing whether the states have kept their promise to use funds from the tobacco settlements—estimated to total $246 billion over the first [...]

Oral Cancer Foundation News Team - A2010-11-17T12:20:18-07:00November, 2010|Oral Cancer News|

Can saliva-based HPV tests establish cancer risk and guide patient management?

Source: Oral and Maxillofacial Pathology doi:10.1016 Author: Mark W. Lingen, DDS, PhD Section Editor, Oral and Maxillofacial Pathology Head and neck squamous cell carcinoma (HNSCC) is the 6th most common malignancy in the world today.1 Despite numerous advances in treatment, the 5-year survival rate has remained modest. This poor outcome is due to several factors, including delayed diagnosis. Therefore, improved early detection and effective prevention strategies are critical components for management of this malignancy. The etiology of classical HNSCC has been attributed to chronic exposure to tobacco and alcohol.2 In addition, there is now sufficient evidence to support the contention that high-risk forms of the human papillomavirus (HPV) are a major causative factor for HNSCC of the tonsil, base of tongue, and oropharynx.3-8 The increasing importance of HPV in oropharyngeal HNSCC has raised considerable concern and uncertainty among healthcare professionals and patients. For example, I am often asked to describe the clinical features of HPV-associated premalignant lesions. Unfortunately, to my knowledge, the clinical spectrum of HPV-associated premalignant disease has not been adequately described. Furthermore, because this subset of HNSCC often develops in hard to- examine locations, such as tonsillar crypts, it can be exceedingly difficult to even identify the carcinomas. In the absence of such information, how can clinicians identify patients that are at increased risk for harboring an HPV-associated premalignant lesions or HNSCC? Recently, a large commercial diagnostic lab began offering a saliva-based test for the identification of oral HPV infections. As a result of this new offering, I [...]

Oral Cancer Foundation News Team - A2010-08-31T12:09:37-07:00August, 2010|Oral Cancer News|

Males can get HPV vaccine Gardasil thanks, in part, to Gulfport cancer survivor

Source: St. Petersburg Times Author: John Barry David Hastings' crusade to inoculate boys against a cancer-causing virus that afflicts women — but threatened him, too — has scored a victory. But it's not quite the one he has been fighting for in the past three years. A panel of the Centers for Disease Control and Prevention last week allowed a vaccine to be given to boys and young men that is already used to protect girls and young women from human papillomavirus, HPV, which causes cervical cancer. The panel's vote followed the Food and Drug Administration's recent okay of the vaccine for boys as a protection against genital warts. The vaccine, Gardasil, was approved only for females, ages 9 to 26, in 2006. But research has since linked HPV to many oral cancers in men. Hastings, who owns the Habana Cafe in Gulfport with his wife, Josefa, testified before the CDC's Advisory Committee on Immunization Practices. He told them how HPV was found in a deadly carcinoma in his throat in 2006. It took seven weeks of simultaneous chemotherapy and radiation at the H. Lee Moffitt Cancer Center in Tampa to arrest the cancer. Ever since, he has spread the message that HPV is a threat to men. He urged the CDC panel to recommend routine vaccinations for boys, as it already does for girls. Hastings and other proponents argued that only 17 percent of girls are completing the series of three doses needed for protection. "We rely on females [...]

Charlotte Parker2009-10-30T10:58:18-07:00October, 2009|Oral Cancer News|